Sussex Research Laboratories Inc. Welcomes Dr. Nycholat as New CSO and Director of U.S. Subsidiary in San Diego
Sussex Research Laboratories Inc. (Sussex Research), a global leader in the translation of complex carbohydrate chemistries into unique, leading-edge products and services that enable researchers to explore and exploit glycomics applications in the promotion of human health, is pleased to announce the appointment of Dr. Corwin Nycholat as Chief Scientific Officer (CSO). Dr. Nycholat had previously served on the Scientific Advisory Board.
"I am delighted to welcome Corwin as our new CSO and director of our U.S. subsidiary in San Diego." - Dr. Brady Clark, President and CEO of Sussex Research
Dr. Corwin Nycholat is a veteran carbohydrate synthetic chemist with over 20 years of experience in developing chemical and enzymatic synthetic processes for complex glycans used in biomedical applications for drug delivery, targeting and vaccine development. Dr. Nycholat’s interests have generally been focused on applications in the fields of glycobiology and glycomics, the study of sugars on a molecular level. He served as a Staff Scientist at The Scripps Research Institute (TSRI) for fifteen years working in the laboratory of Professor James C. Paulson. He has extensive research experience in the synthesis, discovery, and development of high affinity ligands for targeting lectins including siglecs, galectins, and viral hemagglutinins. For 7 years while at TSRI, Dr. Nycholat served as Core Director of the Carbohydrate Synthesis Core under the National Heart, Lung, and Blood Institute funded Lung Inflammatory Disease Program of Excellence in Glycosciences.
“We have been working with carbohydrate/glycan ligands for many years for numerous applications including drug targeting, and Corwin complements our knowledge base in this area perfectly. He has a depth of experience at The Scripps Research Institute developing glycan ligands to probe carbohydrate binding proteins such as Siglecs for applications in immune function regulation. We look forward to applying Corwin’s unique insight in this area to drug and vaccine discovery and development.” - Dr. Brady Clark, President and CEO of Sussex Research